SCHEMBL25822757

SCHEMBL25822757

Brc1ccc2nc(Nc3ccc(C4CCOCC4)cc3)c3nccn3c2c1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.47
IKBKB O14920 1/20 0.41
MAPK8 P45983 7/20 0.39
MAPT P10636 2/20 0.39
MAPK1 P28482 1/20 0.39
AHR P35869 1/20 0.39
HTT P42858 1/20 0.39
LCK P06239 1/20 0.37
JAK3 P52333 1/20 0.37
MAPKAPK5 Q8IW41 4/20 0.36
NPM1 P06748 1/20 0.36
ALK Q9UM73 1/20 0.36
FYN P06241 1/20 0.36
BRD4 O60885 2/20 0.36
H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 P62805 2/20 0.36
MEN1 O00255 1/20 0.35
HPGD P15428 1/20 0.35
KMT2A Q03164 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25822712 0.84 MAPT (0.58) SYKMAPTMAPK1AHRHTT
SCHEMBL25822697 0.82 SYK (0.53) SYKMAPK8LCKMAPKAPK5
SCHEMBL25824383 0.81 MAPK8 (0.43) SYKIKBKBMAPK8LCKJAK3
SCHEMBL25822728 0.79 SYK (0.55) SYK
SCHEMBL25822763 0.78 MAPT (0.46) SYKIKBKBMAPTMAPK1AHR
SCHEMBL25822735 0.77 MAPKAPK5 (0.52) IKBKBMAPTMAPK1AHRHTT
SCHEMBL25822721 0.76 MAPT (0.55) SYKMAPTMAPK1AHRHTT
SCHEMBL15552071 0.75 SYK (0.60) SYKLCKJAK3
SCHEMBL25822743 0.75 SYK (0.48) SYKIKBKBMAPTMAPK1AHR
SCHEMBL31746874 0.75 IKBKB (0.43) IKBKBNPM1ALKMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219960-A1 1H-PYRAZOLE DERIVATIVE AND APPLICATION THEREOF AS DUAL TARGET INHIBITOR OF SYK AND VEGFR2 OCUMENSION THERAPEUTICS (SUZHOU) CO., LTD. (CN) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219960-A1 1H-PYRAZOLE DERIVATIVE AND APPLICATION THEREOF AS DUAL TARGET INHIBITOR OF SYK AND VEGFR2 SYK, KDR, FLT1 SYK 1/4885IKBKB 275/4885MAPK8 637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.